CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
We have now added a new section called the "Assay History List" to the "At A Gla...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...